#Radioembolization with PD vs SD more than doubles survival for advanced #HCC in long-term analysis of #Dosisphere01 (HR 0.51).

>50% of patients downstaged to resection alive at 5 years.

Y90+IO+Surgery next..?

#Multidisciplinary is the way 🧩

jnm.snmjournals.org/content/early/…

Mayo Clinic is participating in Boston Scientific's #FRONTIER trial, assessing the safety & technical feasibility of TheraSphere, Y-90 glass microsphere radiation therapy, in recurrent #glioblastoma patients.
mayocl.in/3UZVqoH
Dr. Alfredo Quiñones-Hinojosa Rabih Tawk Chris Fox, MD, FAANS Beau Bosko Toskich, MD FSIR

#Pembrolizumab + #Y90 for poor prognosis #HCC
doi.org/10.1093/oncolo…

Why is this of interest?
Pilot compared to KEYNOTE-224 cohort 2:

ORR: 30.8 vs 16%
PFS: 9.9 vs 4 months
OS: 27.3 vs 17 months

ROWAN and EMERALD-Y90 further exploring Y90+IO combinations for HCC 🧩

Thank you HCC-LIVE Conference for another incredible event. #HCC LIVE has the perfect mix of high-level, relevant, education and vibrant discussion - all with the most collegial vibe. This is where #HCC ideas are born. Looking forward to next year!

Many thanks HCC-LIVE Conference for the poster of distinction award 🌟 and for hosting such an educational, thought-provoking, multidisciplinary meeting! #HccLive2024 Beau Bosko Toskich, MD FSIR Mayo Clinic Radiology

Ablative #Y90 #radioembolization is now a #BCLC , #AASLD , and #NCCN supported therapy for #HCC .
I congratulate our amazing trainees for their efforts in creating a #RADSEG summary designed for #multidisciplinary #tumorboard participants.🧩

mdpi.com/2072-6694/16/3…

#TACE + #Durvalumab + #Bevacizumab demonstrates superior PFS (23% reduced risk) when compared to #TACE alone for the treatment of #hepatocellularcarcinoma .

Congratulations to the #Emerald1 investigators. Welcome the #combinationtherapy era.🧩

astrazeneca.com/media-centre/p…

#AASLD #HEPATOLOGY cover article:
Overall survival significantly higher in patients with intrahepatic #cholangiocarcinoma treated with the addition of #radioembolization : 21.7 months vs. 15.9 months, HR = 0.59, p = 0.049. 🧩

RCT even feasible?

journals.lww.com/hep/abstract/2…

High specific activity matters in current #Y90 #TARE #HCC practice. Tumor microdose environment should be further investigated. 🧩 #limitedseats #legolasparticle #brighterlightbulbs #radiationpermicrosphere

What specific activity (aka radiation per microsphere) do you choose when treating solitary #hepatocellularcarcinoma <8 cm with ablative #Y90 #TARE ?

#TRANSPLANTONCOLOGY helps select patients with #ColonCancer liver mets. #EPOCH showed superior disease control by adding #Y90 to systemic therapy. #TARE does not compromise the hepatic artery.
If #MELD exception becomes reality, time to discuss #BRIDGING . #windowofopportunity 🧩

Immunotherapy alone with #STRIDE for #HCC improves survival. Combining with current #Y90 TARE practice in the #ROWAN study is a timely and #RELEVANT next step. 🧩

This is a significant change in perception from 5 years ago. #LEGACY #RASER #RADPATH 🧩

🔥EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma🔥
Journal of Hepatology
doi.org/10.1016/j.jhep…
👏Very detailed recommendations on diagnostic, prognostic, and therapeutic management of iCCA
ESMO - Eur. Oncology EASL Education ENS-CCA #livertwitter OncoAlert

#Y90 radiation segmentectomy for the treatment of solitary #HCC at your institution is considered:

Another fantastic #MayoClinic HPB Cancer Symposium: ✅️

Thank you again Tanios Bekaii-Saab, MD Mitesh Borad, M.D. Dan Duda and Sean Cleary for the invitation!

Emerald-1 is positive. How will the data readout impact your MDT?🧩
astrazeneca.com/media-centre/p… #HCC #AstraZeneca #Durvalumab #TACE #combinationtherapy

Excited to announce 1st patient enrollment in the #ROWANstudy by Dan Giardina, MD and Chris Malone Washington University in St. Louis to assess the efficacy of #TheraSphere #Y90 Glass Microspheres followed by Tremelimumab with Durvalumab in patients with #HCC Learn more: bit.ly/46Og1iN